Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06213649 · ClinicalTrials.gov registry record · Phase 3
Parasitic Ulcer Treatment Trial
A Phase 3 study of Acanthamoeba Keratitis, sponsored by Jeremy Keenan, MD, MPH.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
- 16
- Study locations
NCT06213649 is a Phase 3 study of Acanthamoeba Keratitis that is actively recruiting participants, run by Jeremy Keenan, MD, MPH. The registered enrollment target is 232 participants. The trial reports 16 study locations across 12 states.
The verdict
NCT06213649, a Phase 3 study of Acanthamoeba Keratitis, is actively recruiting participants, sponsored by Jeremy Keenan, MD, MPH.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
- 16
- Study locations
Study Summary
The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers with evidence of acanthamoeba keratitis will be eligible for the trial if there is evidence of ocular inflammation after 4 weeks of anti-amoebic therapy. Those who agree to participate will be randomized to one of two treatment groups: * Group 1: Topical corticosteroid * Group 2: Topical placebo
Conditions Studied
Interventions
- DRUG Polyhexamethylene biguanide (PHMB)
- DRUG Topical corticosteroid
- OTHER Topical placebo
Study Locations (16)
Florida
- University of Florida - Gainesville
- University of Miami - Miami
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Other
- Federal University of São Paulo - São Paulo
- Moorfields Eye Hospital - London
Tamil Nadu
- Aravind Eye Hospital - Coimbatore
- Aravind Eye Hospital - Madurai
California
- University of California, San Francisco - San Francisco
Illinois
- University of Illinois, Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06213649
The ClinicalTrials.gov registry entry for NCT06213649 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeremy Keenan, MD, MPH, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acanthamoeba Keratitis appearing as the primary indexed condition, and to 3 interventions - of which Polyhexamethylene biguanide (PHMB) is the first listed.
NCT06213649 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Florida, Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT06213649 about?
NCT06213649 is a clinical study titled "Parasitic Ulcer Treatment Trial". The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers...
What is the current status of trial NCT06213649?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2024-07-01. Estimated completion is 2028-07.
What conditions does trial NCT06213649 study?
This clinical trial studies the following conditions: Acanthamoeba Keratitis.
What interventions are being tested in trial NCT06213649?
The interventions under investigation include: Polyhexamethylene biguanide (PHMB) (DRUG), Topical corticosteroid (DRUG), Topical placebo (OTHER).
Who is sponsoring clinical trial NCT06213649?
This trial is sponsored by Jeremy Keenan, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06213649 being conducted?
This trial has 16 study locations across California, Florida, Illinois, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.